As pharma giants Eli Lilly NYSE: LLY and Novo Nordisk NYSE: NVO are raking in the cash from their weight loss and diabetes drugs, many other companies want a piece of the pie. They’re developing treatments to improve upon the deficiencies of Lilly and Novo’s drugs. Altimmune TodayALTAltimmune$7.46 +0.15 (+2.05%) 52-Week Range$2.32▼$14.84Price Target$18.80Add to WatchlistOne company to keep an eye on in this space is Altimmune NASDAQ: ALT. But what makes Altimmune's drug different from existing drugs, and w ...